Status:
UNKNOWN
Intranasal Esketamine and Fentanyl for Pain in Minor Trauma
Lead Sponsor:
Anna Meuronen, MD
Conditions:
Acute Pain Due to Trauma
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Intranasal esketamine, fentanyl and placebo are compared in treatment of acute pain in adult patients with minor trauma. Study is blinded randomized placebo-controlled parallel design.
Eligibility Criteria
Inclusion
- NRS 5 or more, minor trauma, no need for immediate iv cannulation, weight 45-115 kg
Exclusion
- pregnancy, breastfeeding, head trauma, severe chronic obstructive pulmonary disease (COPD), gfr under 30, liver cirrhosis, mental illness other than mild/moderate depression, sleep apnea, unstable coronary artery disease (CAD), unstable heart failure (HF), intoxication, untreated hypertension, dementia, do not understand Finnish, contraindication to nasal spray, allergy to any of the medications, bradycardia, desaturation, suspected high intracranial pressure (ICP)
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT03421275
Start Date
December 1 2017
End Date
December 1 2022
Last Update
February 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hyvinkää Hospital
Hyvinkää, Finland